BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 2022. [PMID: 34997230 DOI: 10.1038/s41571-021-00588-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 42.0] [Reference Citation Analysis]
Number Citing Articles
1 Alonso-miguel D, Fiering S, Arias-pulido H. Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes. Cells 2022;11:2850. [DOI: 10.3390/cells11182850] [Reference Citation Analysis]
2 Mansouri S, Heylmann D, Stiewe T, Kracht M, Savai R. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. Elife 2022;11:e79895. [PMID: 36074553 DOI: 10.7554/eLife.79895] [Reference Citation Analysis]
3 Hu Z, Zhou J, Li Y, Luan Y, Li H, Jia B, Xie Z, Cheng B, Wu T. Peripheral immune signature resembles tumor microenvironment and predicts clinical outcomes in head and neck squamous cell carcinoma. Front Immunol 2022;13:915207. [DOI: 10.3389/fimmu.2022.915207] [Reference Citation Analysis]
4 Li R, Xue K, Li J. FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches. Front Med 2022. [PMID: 36053411 DOI: 10.1007/s11684-022-0944-z] [Reference Citation Analysis]
5 Yan W, Lang T, Yuan W, Yin Q, Li Y. Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy. Acta Pharmacol Sin. [DOI: 10.1038/s41401-022-00976-6] [Reference Citation Analysis]
6 Zhang H, Yang K, Chen F, Liu Q, Ni J, Cao W, Hua Y, He F, Liu Z, Li L, Fan G. Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications. Front Immunol 2022;13:975367. [DOI: 10.3389/fimmu.2022.975367] [Reference Citation Analysis]
7 Yu C, Li Q, Zhang Y, Wen Z, Dong H, Mou Y. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. Front Cell Dev Biol 2022;10:941750. [DOI: 10.3389/fcell.2022.941750] [Reference Citation Analysis]
8 Zhao N, Yi Y, Cao W, Fu X, Mei N, Li C. Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. Front Oncol 2022;12:923531. [DOI: 10.3389/fonc.2022.923531] [Reference Citation Analysis]
9 Li R, Wu X, Xue K, Li J. ITGAL infers adverse prognosis and correlates with immunity in acute myeloid leukemia. Cancer Cell Int 2022;22:268. [PMID: 35999614 DOI: 10.1186/s12935-022-02684-x] [Reference Citation Analysis]
10 Mao X, Yang C, Yang Y, Yan L, Ding Z, Liu H, Yan Y, Dong Z, Wang D, Li T. Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front Immunol 2022;13:884592. [DOI: 10.3389/fimmu.2022.884592] [Reference Citation Analysis]
11 Mukherjee AG, Wanjari UR, Prabakaran DS, Ganesan R, Renu K, Dey A, Vellingiri B, Kandasamy S, Ramesh T, Gopalakrishnan AV. The Cellular and Molecular Immunotherapy in Prostate Cancer. Vaccines (Basel) 2022;10:1370. [PMID: 36016257 DOI: 10.3390/vaccines10081370] [Reference Citation Analysis]
12 Li Z, Qin Z, Kong X, Chen B, Hu W, Lin Z, Feng Y, Li H, Wan Q, Li S. CCL14 exacerbates intraplaque vulnerability by promoting neovascularization in the human carotid plaque. J Stroke Cerebrovasc Dis 2022;31:106670. [PMID: 35973397 DOI: 10.1016/j.jstrokecerebrovasdis.2022.106670] [Reference Citation Analysis]
13 Zhu Y, Qin LX. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00189-8. [PMID: 35977874 DOI: 10.1016/j.hbpd.2022.08.003] [Reference Citation Analysis]
14 Shemesh A, Pickering H, Roybal KT, Lanier LL. Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion. J Exp Med 2022;219:e20212434. [PMID: 35758909 DOI: 10.1084/jem.20212434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Liu J, Zhang C, Li R, Man Q, Siemianowicz K. IL-8 Is Upregulated in the Tissue-Derived EVs of Odontogenic Keratocysts. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/9453270] [Reference Citation Analysis]
16 Sabit H, Abdel-hakeem M, Shoala T, Abdel-ghany S, Abdel-latif MM, Almulhim J, Mansy M. Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs. Pharmaceutics 2022;14:1566. [DOI: 10.3390/pharmaceutics14081566] [Reference Citation Analysis]
17 Swati, Sharma V. The interplay of cytokine signaling and non-coding RNAs in head and neck squamous cell carcinoma pathobiology. Mol Biol Rep. [DOI: 10.1007/s11033-022-07770-x] [Reference Citation Analysis]
18 Huang H, Zhu Q, Ga M, Wu D, Meng X, Wang S, Fang H, Tang Y, Li N. Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States. Front Oncol 2022;12:930846. [DOI: 10.3389/fonc.2022.930846] [Reference Citation Analysis]
19 Baram T, Oren N, Erlichman N, Meshel T, Ben-baruch A. Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFα Receptors in Human Triple-Negative Breast Cancer. Cancers 2022;14:3513. [DOI: 10.3390/cancers14143513] [Reference Citation Analysis]
20 Yang D, Li H, Chen Y, Li C, Ren W, Huang Y. A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy. Front Genet 2022;13:906174. [DOI: 10.3389/fgene.2022.906174] [Reference Citation Analysis]
21 Chen J, Wang Y, Shen L, Xiu Y, Wang B. Could IL-25 be a potential therapeutic target for intestinal inflammatory diseases? Cytokine Growth Factor Rev 2022:S1359-6101(22)00051-X. [PMID: 35840510 DOI: 10.1016/j.cytogfr.2022.07.001] [Reference Citation Analysis]
22 Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J, Coosemans A, Datsi A, Fučíková J, Kinget L, Neyns B, Schreibelt G, Smits E, Sorg RV, Spisek R, Thielemans K, Tuyaerts S, De Vleeschouwer S, de Vries IJM, Xiao Y, Garg AD. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology 2022;11:2096363. [DOI: 10.1080/2162402x.2022.2096363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Ben-Baruch A. Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy. Front Immunol 2022;13:903679. [PMID: 35663982 DOI: 10.3389/fimmu.2022.903679] [Reference Citation Analysis]
24 Nie W, Chen J, Wang B, Gao X. Nonviral vector system for cancer immunogene therapy. MedComm – Biomaterials and Applications 2022;1:mba2.10. [DOI: 10.1002/mba2.10] [Reference Citation Analysis]
25 Shang Q, Dong Y, Su Y, Leslie F, Sun M, Wang F. Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy. Adv Drug Deliv Rev 2022;185:114308. [PMID: 35472398 DOI: 10.1016/j.addr.2022.114308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Yan L, Hu C, Ji Y, Zou L, Zhao Y, Zhu Y, Wang X, Yu X. Identification of Significant Secreted or Membrane-Located Proteins in Laryngeal Squamous Cell Carcinoma. Journal of Immunology Research 2022;2022:1-11. [DOI: 10.1155/2022/9089397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Rao J, Xu N, Sun J, Li Y, Fu F. Case Report: Interferon-Alpha-Induced Neuromyelitis Optica Spectrum Disorder. Front Neurol 2022;13:872684. [PMID: 35547376 DOI: 10.3389/fneur.2022.872684] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Jiang H, Cui J, Chu H, Xu T, Xie M, Jing X, Xu J, Zhou J, Shu Y. Targeting IL8 as a sequential therapy strategy to overcome chemotherapy resistance in advanced gastric cancer. Cell Death Discov 2022;8:235. [PMID: 35487914 DOI: 10.1038/s41420-022-01033-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]